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A B S T R A C T

BACKGROUND: Chemotherapy-resistant cancer stem cells (CSC) may lead to tumor recurrence in glioblastoma (GBM).
The poor prognosis of this disease emphasizes the critical need for developing a treatment stratiﬁcation system to improve
outcomes through personalized medicine. METHODS: We present a case series of 12 GBM and 2 progressive anaplastic
glioma cases from a single Institution prospectively treated utilizing a CSC chemotherapeutics assay (ChemoID) guided
report. All patients were eligible to receive a stereotactic biopsy and thus undergo ChemoID testing. We selected one of
the most effective treatments based on the ChemoID assay report from a panel of FDA approved chemotherapy as monotherapy or their combinations for our patients. Patients were evaluated by MRI scans and response was assessed according
to RANO 1.1 criteria. RESULTS: Of the 14 cases reviewed, the median age of our patient cohort was 49 years (21–63). We
observed 6 complete responses (CR) 43%, 6 partial responses (PR) 43%, and 2 progressive diseases (PD) 14%. Patients
treated with ChemoID assay-directed therapy, in combination with other modality of treatment (RT, LITT), had a longer
median overall survival (OS) of 13.3 months (5.4-NA), compared to the historical median OS of 9.0 months (8.0–10.8
months) previously reported. Notably, patients with recurrent GBM or progressive high-grade glioma treated with
assay-guided therapy had a 57% probability to survive at 12 months, compared to the 27% historical probability of survival observed in previous studies. CONCLUSIONS: The results presented here suggest that the ChemoID Assay has the
potential to stratify individualized chemotherapy choices to improve recurrent and progressive high-grade glioma patient
survival.
Importance of the Study: Glioblastoma (GBM) and progressive anaplastic glioma are the most aggressive brain tumor in
adults and their prognosis is very poor even if treated with the standard of care chemoradiation Stupp's protocol. Recent
knowledge pointed out that current treatments often fail to successfully target cancer stem cells (CSCs) that are responsible
for therapy resistance and recurrence of these malignant tumors. ChemoID is the ﬁrst and only CLIA (clinical laboratory
improvements amendment) -certiﬁed and CAP (College of American Pathologists) -accredited chemotherapeutic assay
currently available in oncology clinics that examines patient's derived CSCs susceptibility to conventional FDA (Food
and Drugs Administration) -approved drugs. In this study we observed that although the majority of our patients
(71.5%) presented with unfavorable prognostic predictors (wild type IDH-1/2 and unmethylated MGMT promoter), patients treated with ChemoID assay-directed therapy had an overall response rate of 86% and increased median OS of
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13.3 months compared to the historical median OS of 9.1 months (8.1–10.1 months) previously reported [1] suggesting
that the ChemoID assay may be beneﬁcial in personalizing treatment strategies.

Introduction

enrichment procedure and the assay have been previously described
[10–12]. The bulk of tumor cells and CSCs were counted using trypan blue
exclusion to determine cellular viability and cell number prior to
chemosensitivity testing. Cells were also incubated with ﬂorescent antibodies
for phenotypic characterization by ﬂow cytometry and also this procedure
has been previously described [10,11]. Percent of cell survival was assessed
using an MTT assay on 1 × 10∧3 cells plated in 5 replicas into 96-well plates.
An equal number of the bulk of tumor cells and CSCs were seeded in 96-well
dishes and incubated at 37 °C for 24-hours. Three concentrations of each chemotherapy treatment were prepared by serial dilution. Each concentration
was added to ﬁve replicate wells on the microtiter plate. Additionally, three
replicates wells (control 1 = no treatment) and three replicates wells (control
2 = equal amount of solvent) were associated with each treatment. The cells
were challenged for a 1-hour pulse with the panel of anticancer drugs
(Table 1). MTT assay was performed 24-hours following chemotherapy treatment to assess cell survival as previously described [10–12].
Inhibition of bulk of tumor cells and CSCs survival was measured for
each concentration (average counts in ﬁve replicates ± SE) of a given treatment (15–18 per patient). Survival of tumor cells at each concentration was
calculated as compared to control-2 and overall percent of the bulk of
tumor cells and CSCs killed were calculated for each treatment as the primary measures of potential therapy efﬁcacy.

Glioblastoma (GBM) and progressive anaplastic glioma are the most aggressive brain tumor in adults, exhibiting a very poor prognosis with a median
time to recurrence for GBM of approximately 7 months, and a median survival
of 15–18 months even if treated with standard of care consisting of surgical
resection/biopsy, and concurrent radiation with Temozolomide followed by
adjuvant Temozolomide (TMZ) [2]. Despite this treatment, recurrence is almost inevitable, [3] and the prognosis of recurrent GBM remains poor with
a median PFS of 5.5 months, and a median OS of 8–9 months [4]. Unfortunately, no universally held standard of care is available for recurrent GBM
and progressive anaplastic glioma. Treatment options depend on speciﬁc aspects of its presentation, including secondary cytoreductive surgery when
possible, focused re-irradiation [5], and numerous second-line chemotherapy
treatment options [6]. While most patients eventually succumb to the progression of recurrent disease, second-line chemotherapy treatments have provided variable remission and symptom-free survival in a percentage of
patients [6]. As such, the selection of effective chemotherapy is extremely important for these patients. Additionally, with emerging value-based payment
models where outcomes-based contracts link to payment for indications of
speciﬁc cancer drug prices, there are further concerns about the accessibility
and affordability for treatment of recurrent GBM patients; therefore, there is a
need for effective treatments that limit overall cost while also increasing treatment value for these patients.
Herein we describe our experience in using ChemoID, a clinical laboratory improvements amendment (CLIA)-certiﬁed and College of
American Pathologists (CAP)-accredited clinical diagnostic test that is
performed in a clinical pathology laboratory, which identiﬁes chemotherapeutic agent(s) that kill both the cancer stem cells (CSCs) and the
bulk tumor cells, to guide treatment of recurrent GBM and progressive
anaplastic glioma.

Statistical Analysis
Descriptive statistics were constructed as medians with ranges for continuous variables and counts and percentages for categorical variables.

Table 1
List of single chemotherapeutic agents and combinations tested on the GBM and
progressive high-grade glioma cohort and clinical dose

Methods
Patients
Fourteen patients (11 males and 3 females), 18 years and older, that were
clinically diagnosed with recurrent GBM (12 patients) or progressive anaplastic glioma (2 patients), received a concurrent stereotactic biopsy for histological diagnosis and for prospective ChemoID chemotherapeutic testing between
October 2016 and October 2017. This study was approved by the Institutional
Review Board (IRB) and informed consent was obtained. Patients were treated
with ChemoID-guided chemotherapy according to their overall functional status and ability to tolerate the recommended treatment. Radiological data was
collected before surgery, immediately post-surgery and following chemo/radiation therapy with an MRI follow-up every 2 months. Supportive care was
also allowed at the discretion of the treating physician. Disease status was measured by radiologic examination (MR scan as the primary imaging method),
physical examination, and measurements using the Response Assessment in
Neuro-Oncology (RANO 1.1) criteria [7], which takes into account parameters
and evaluations to identify pseudo-progression as well as pseudo-response.
The RANO criteria, similarly to other systems, divide response into 4 types
of response based on imaging (MRI) and clinical features [8,9]: complete response, partial response, stable disease, and progression.

Single drug

Dose

1

Carboplatin

2

Irinotecan

3
4

Etoposide
BCNU

5

CCNU

6

Temozolomide

7
8
9

Procarbazine
Vincristine
Imatinib
Drug
Combinations
Procarbazine
CCNU

350
mg/m2
125
mg/m2
50 mg/m2
100
mg/m2
100
mg/m2
200
mg/m2
60 mg/m2
1.4 mg/m2
400 mg
Dose

1

2

Vincristine
Carboplatin
Irinotecan

3

ChemoID Assay
4

Multiple fresh GBM tissue samples for ChemoID functional testing were
collected in the operating room from each patient at the time of the stereotactic biopsy procedure. Details regarding cell culture conditions, the CSCs
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2

Carboplatin
Etoposide
Temozolomide
Etoposide
Temozolomide
Imatinib

60 mg/m2
100
mg/m2
1.4 mg/m2
350
mg/m2
125
mg/m2
350
mg/m2
50 mg/m2
50 mg/m2
50 mg/m2
50 mg/m2
200 mg

3

No
No
Yes
Yes
Yes
Yes
Yes
Yes
Yes
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
Yes
No
No
No
No
No
No
Yes
No
No
Yes
No
Yes
No
Yes

Yes
Yes
Yes
Yes
80
70
60
60

CR
CR
PR
CR
PR
CR
PR
PR
PR
No
No
No
Yes
Yes
Yes
Yes
Yes
Yes
F
M
M
M
M
M
M
M
M
49
56
61
21
52
35
63
36
33
7
8
9
10
11
12
13
14

F
M
M
49
60
48
3
4
5
6

No
No
Yes

CR
PD
CR

Wild-type Unmethylated Right Temporal
Wild-type Unmethylated Left Temporal
Wild-type Unmethylated Right Frontal
Diffuse, Right Frontal,
Mutant
Unmethylated Parietal, Temporal
Wild-type Methylated
Left Temporal
Wild-type Unmethylated Left Temporal
Wild-type Unmethylated Left Thalamus and Midbrain
Wild-type Unmethylated Right Frontal/Insula
Wild-type Unmethylated Left Occipital
Mutant
Methylated
Left Frontal-Temporal
Wild-type Unmethylated Right Temporal
Wild-type Unmethylated Diffuse, Right Frontal,
Temporal

90
90
90
70
70
80
70
70

No
No
Yes
No
No
No
No
No
No
No
No
No

Yes
No
No
No
Yes
No

No
Yes
(for infection)
No
No
No
No
Yes
No
80
70
Wild-type Methylated
Left Frontal, Multifocal
Wild-type Unmethylated Right frontal, Multifocal
32
60
1
2

6 (43%)
6 (43%)
0 (0%)
2 (14%)

Age at
diagnosis

49 / (21–63)
3 (21%)
11 (79%)
12/14 (86%)
10/14 (71%)

Patient
number

Median age
Female
Male
IDH-1/2 wild-type
Unmethylated MGMT promoter
Response
Complete response (CR)
Partial response (PR)
Stable disease (SD)
Progressive disease (PD)

Table 3
Patients' detailed characteristics

Table 2
Patient characteristics

Gender Alive Response by
RANO 1.1

IDH-1/2

MGMT
Promoter
Methylation
Status

Tumor
Location

KPS
Status

Surgery before
ChemoID

Repeat Surgical
Resection after
ChemoID/Biopsy

LITT before
ChemoID

LITT after
ChemoID

Fresh tissue samples were collected for drug sensitivity testing from 12
GBM and 2 progressive anaplastic glioma patients, with a median age of 49
years (range 21–61), 79% of which were male, all eligible for stereotactic
biopsy. Patients were treated with chemotherapies predicted to be most efﬁcacious by the ChemoID chemotherapeutics assay taking into consideration the patient's tolerability of that particular treatment based on their
health status.
IDH-1 mutation and methylation status of the promoter region of the
O6-Methyl-guanyl-methyl-transferase (MGMT) gene were studied for our
entire patient cohort. About 29% of our patients had methylation of the
MGMT gene promoter, and 86% a wild-type IDH-1/2 status from their pathology report (Table 2).
Table 3 reports the clinical characteristics we have analyzed in our patient cohort. In particular, 10 patients (72%) presented with IDH-1/2
wild-type and unmethylated MGMT promoter, 2 patients (14%) with
IDH-1/2 wild-type and methylated MGMT promoter, 1 patient (7%) with
IDH-1 mutated and unmethylated MGMT promoter, and 1 patient (7%)
with IDH-1/2 mutated and a methylated MGMT promoter, indicating that
the vast majority of the patients in our cohort had negative prognostic predictors for their disease (i.e. presence of wild-type IDH-1/2 protein and
unmethylated MGMT gene promoter) [13–16]. The median KPS status of
our patients was 70 (KPS range 60–90). 57% of our patients were reirradiated following ChemoID guided therapy. Only one patient in our cohort underwent surgical resection as part of the treatment for their recurrent GBM, and another one was operated on as a treatment for an infection.
Patients were prospectively monitored by response assessment in
neuro-oncology (RANO 1.1) for tumor response, time to progression,
progression-free survival (PFS), and overall survival (OS). Tables 2 and 3
describe the characteristics of our patient series and their response to therapy observed as per RANO 1.1. We observed 6 complete responses (CR)
43% (6 out of 14 patients), 6 partial response (PR) 43% (6 out of 14 patients), and 2 progressive diseases (PD) 14% (2 out of 14 patients). However, the two PD (patients #2 and 4, Figure 1) were observed because
patients could not be treated with ChemoID recommended therapy for
their health status.
All patients had follow-up MRI every 2 months, and the median followup from pre-ChemoID tumor biopsy was 11.4 months (range 4.0–29.4
months). At the end of our follow-up, 7 patients (50%) were still alive.
Figure 1 shows survival times of the recurrent GBM patients prospectively
treated using the ChemoID test results and chemotherapies predicted by
the CLIA-certiﬁed and CAP-accredited CSC drug assay.
We observed that the median OS of patients treated with ChemoID
assay-directed therapy was 13.3 months (5.4-NA) compared to the historical median OS of 9.1 months (8.1–10.1 months) previously reported

PR
PD

Patients' Survival Analysis

No
No

Results

M
F

Irradiation before
ChemoID

Irradiation after
ChemoID

Due to the small sample size, no survival models were constructed. A graph
displaying censoring/death times for each participant with annotations was
constructed along with a Kaplan–Meier plot showing survival probabilities.
All statistics and graphics were compiled using Stata v15.1 (StataCorp, College Station, TX).

Yes
No
No
Yes
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has proven to be problematic, the management of these patients remains
difﬁcult.
TMZ is a key component of standard therapy for both newly diagnosed
and recurrent GBM patients; however, the major challenge with recurrent
GBM treatment is the numerous clinically-acceptable and oftentimes equivalent treatment options identiﬁed in treatment guidelines [20] . Currently,
there is insufﬁcient evidence to indicate a superior agent or treatment strategy for GBM patients as a whole as well as for the individual patient.
The presence of CSCs appears to be responsible, at least in part, for resistance to standard treatments, the variable responses seen to treatment, and
thus has important implications for the development of a diagnostic assay
to guide personalized treatment regimens [21]. The current study evaluated the clinical advantage of using the ChemoID chemotherapeutics
assay to measure CSC response against a panel of FDA approved chemotherapies to treat recurrent GBM. Patients were treated with chemotherapies
(Table 1) chosen from those drugs showing the highest cell kill as determined by the CSCs and bulk of tumor chemotherapeutic test response,
and by taking into consideration the patient's tolerability of the treatment.
This study is the ﬁrst example demonstrating that ChemoID, a CSC chemotherapeutics assay, can prospectively identify and stratify more effective
chemotherapy agents versus other possible choices on an individual patient
level in poor prognosis recurrent GBM and progressive anaplastic glioma. In
particular, although 10/14 of our patient cohort (71.5%) presented with
unfavorable prognostic predictors (IDH-1/2 wild type and unmethylated
MGMT promoter) [13–15], we observed that patients treated with
ChemoID assay-directed therapy had an overall response rate of 86%. Notably, PD was observed in those patients that could not be treated with assay
recommended therapy due to their health status and co-morbidities.
Interestingly, systematic reviews and meta-analysis of re-resection and
re-irradiation for recurrent GBM showed that both practices were associated with better overall survival and post-progression survival, providing
encouraging disease control and survival rates [22,23]. 57% of the GBM patients in our cohort, received irradiation following ChemoID guided therapy, but only two recurrent patients underwent surgical resection as part
of their treatment, with one of the two patients that were operated to
treat an infection and not the neoplastic lesion.
It is known that recurrent GBM is associated with a median overall survival of less than a year and the majority of patients have profound tumorrelated symptoms [24,25]. Interventions such as re-resection, systemic
therapy and/or re-irradiation may beneﬁt selected patients, but unfortunately, all are given with a palliative intent [25]. As such, treatment

(Figure 2) [1]. Notably, our recurrent and progressive high-grade glioma
patient cohort treated with ChemoID assay-guided therapy had a 57% probability to survive at 12 months, compared to the 27% historical probability
of survival at 12 months observed in previous studies [17]. Of the surviving
patients, all have exceeded the expected survivals of previously reported
studies [1,4,17]. One-year overall survival was 57% (95% CI: 28% 78%), based upon Kaplan–Meier estimates.
Figure 3 shows the MRI image of a wild type IDH-1, unmethylated
MGMT, non-operable left midbrain/thalamus GBM patient (Figure 3A),
the ChemoID drug response assay results (Figure 3B), and the subsequent
MRI images (Figure 3, C–H) following treatment with ChemoID-guided
therapy and re-irradiation. This patient received a stereotactic biopsy for
an inoperable left brainstem mass to conﬁrm the presence of a grade IV glioblastoma in December of 2016. A concomitant fresh biopsy was sent to the
ChemoID lab for testing. The patient was treated with a full course of irradiation to 60 Gy and Temozolomide (TMZ) as per standard of care; however, the tumor showed radiologic progression in April 2017 (Figure 3C).
At this point, after multidisciplinary discussion, treatment was switched
to BCNU, which had demonstrated bulk tumor effectiveness (88.6% cell
kill) as well as CSC (82.6% cell kill) by the ChemoID assay. MRI images
in November of 2017 following the completion of treatment with 6 cycles
of BCNU (150 mg/m2 every 6 weeks) showed a dramatic reduction of the
tumor burden (Figure 3D). Patient requested maintenance therapy and
was then reirradiated and started on Imatinib (400 mg daily), which also
demonstrated effectiveness on the bulk of tumor (96.3% cell kill) and on
CSC (45.9% cell kill) by the ChemoID assay. MRI images following treatment with Imatinib (February–November 2018) showed an even greater reduction of the tumor burden for 24 months with no new lesions (Figure 3,
E–H).

Discussion
Medical management of recurrent GBM and progressive anaplastic glioma is typically a multimodality treatment plan consisting of maximal
safe surgical resection (when possible), followed by radiotherapy with concomitant and adjuvant Temozolomide and/or other secondary chemotherapies [4,18,19] which continually increases treatment morbidity leading to
further cost with diminishing returns on the outcome. Moreover, despite
aggressive therapy and emerging chemotherapeutic treatment options, because current therapies are not curative and improving overall survivability

Figure 1. Diagram illustrating patient's characteristics, their survival times in months, and their response to treatment according to RANO 1.1 criteria. Abscissae axis shows
survival time in months, ordinate axis shows patient number. Dashed lines indicate deaths, while solid lines indicate right censoring. Treatment response according to RANO
1.1 criteria is indicated by Complete Response (CR), Partial Response (PR) and Progressive Disease (PD).
4
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Figure 2. Kaplan-Meier plot of overall survival probability. Overall survival (OS) for recurrent GBM patients treated with ChemoID-guided responsive drugs. Patients
receiving ChemoID responsive drugs had a median survival of 13.3 months. Twelve months survival probability was 57% (95% CI: 28% to 78%), based upon Kaplan–
Meier estimates.

survival (OS), OS at 6, 9, and 12 months, median progression-free survival
(PFS), PFS at 4, 6, 9, and 12 months, objective tumor response, time to recurrence, and quality of life.
ChemoID is the ﬁrst and only chemotherapeutics assay currently available in oncology clinics that examines CSCs susceptibility to conventional
FDA approved drugs from solid tumors. Results from the current study indicate that the ChemoID assay may be a very useful tool for optimizing treatment selection when ﬁrst-line therapy fails, and when there are multiple
clinically acceptable and equivalent treatments available. The ChemoID
assay takes 2 weeks to be completed from the date of receiving a live biopsy, which corresponds to the average time patients spend recovering
from surgery prior to continuing further therapy. Therefore, the ChemoID
assay is suitable for timely, individualized chemotherapy for cancer patients who received surgery. Furthermore, our results suggest that this individualized functional chemotherapeutic assay may indeed surpass the
results achieved by empiric population-based treatment by providing
more treatment options with improved outcomes for many more patients.
This compelling data suggests that the ChemoID CSC assay may be beneﬁcial in personalizing treatment strategies to increase survival time for recurrent GBM patients and to provide quality metrics for healthcare payers and
providers to support access to care.

decisions must be individualized. Clinicians are tasked with selecting the
most appropriate treatment, balancing the beneﬁts of treatment with the
risk of treatment-related toxicity and its impact on the quality of life
[26,27]. The performance status of the patient, extent of recurrence (focal
versus diffuse) and location of recurrence are important considerations in
such instances [26,27].
Notably, our cohort of GBM and progressive high-grade glioma patients
treated with assay-guided therapy had a 57% probability to survive at 12
months, compared to the 27% historical probability of survival at 12
months observed in previous studies [1,4,17], demonstrating the importance of determining CSCs response to chemotherapy to prolong patients'
survival. The data further supports the belief that long-term tumor response
in GBM, is in fact, more dependent on the intrinsic sensitivity or resistance
of the CSCs to conventional chemotherapies. This concept is especially
valuable and important with emerging value-based healthcare models
where outcomes-based contracts linked to payment for an indication of speciﬁc anticancer-drug prices raise concerns about the accessibility and affordability for treatment of recurrent GBM patients. The power of
precision medicine lies in its ability to guide health care decisions toward
the most effective treatment for a given patient, and thus, improve care
quality while reducing the need for unnecessary diagnostic testing and
therapies.
ChemoID is a functional precision medicine test that uses patient's live
bulk of tumor cells and cancer stem cells (CSCs) isolated by tumor biopsies
to indicate and to stratify which chemotherapy agent (or “combinations”) is
most effective [12]. Targeting of CSCs alongside the bulk of other cancer
cells is a new paradigm in personalized anticancer treatment. This strategy
and technological advancement constitute an important advantage of
ChemoID approach over other diagnostic methods for personalized
medicine.
We are currently conducting a multi-institutional phase-III clinical trial
(NCT03632135) to determine the clinical validity of the ChemoID assay as
a predictor of clinical response in recurrent GBM. The study has been designed as a parallel-group, controlled clinical trial that randomizes participants to either standard of care chemotherapy chosen by the physician or
ChemoID-guided therapy. In the NCT03632135 trial, response to therapy
will be measured by MRI imaging using RANO 1.1 criteria to assess overall
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after obtaining patients' written informed consent in accordance with the
ethical standards of the Helsinki Declaration (1964, amended most recently
in 2008) of the World Medical Association.
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Figure 3. MRI Images and comparative analysis of ChemoID test results on Bulk of Tumor and Cancer Stem Cells of a patient affected by left midbrain/thalamus, WHO grade
4, IDH wild-type, MGMT unmethylated gene, not operable, recurrent GBM. A) Preoperative (stereotactic biopsy) MRI shows an intra-axial enhancing mass centered in the left
midbrain/thalamus measuring 2.51 × 1.49 cm (12/22/2016). B) Comparative ChemoID analysis on Bulk of Tumor and Cancer Stem Cells obtained from fresh stereotactic
biopsy. C) Control MRI (04/06/2017) following standard of care treatment with Temodar chemotherapy (75 mg/m2 daily) and radiation therapy (with radiation boost – 7
fractions) shows increased size of the left midbrain/thalamus lesion measuring 2.93 × 1.86 cm. D) Failure of standard of care treatment prompted treatment with BCNU (150
mg/m2 every 6 weeks). Control MRI (11/08/2017) after 6 cycles of BCNU shows initial regression of the lesion measuring 1.53 × 0.95 cm. E) Control MRI (02/20/2018)
following Imatinib (400 mg daily) treatment shows regression of the lesion measuring 9.66 × 7.16 mm. F) Control MRI (05/14/2018) following continued Imatinib (400 mg
daily) treatment shows stable lesion measuring 9.62 × 7.25 mm. G) Control MRI (07/19/2018) following continued Imatinib (400 mg daily) treatment shows stable lesion
measuring 9.54 × 7.22 mm. H) Control MRI (11/21/2018) following continued Imatinib (400 mg daily) treatment shows stable lesion measuring 9.66 × 7.16 mm.
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